Petco Health & Wellness Company, Inc. — Form 10-Q Summary
Reporting period: The filing covers the 13 and 39 weeks ended October 29, 2022, compared with the periods ended October 30, 2021. Although the request metadata labels this “2021 Q3,” the filing itself reports fiscal 2022 third-quarter results. Amounts below are in U.S. dollars.
Business context and performance
Petco operates an omnichannel pet health and wellness business, including retail, e-commerce, grooming and veterinary services. It reported one operating segment and approximately 1,428 pet care centers at period-end. Management cited more than 25 million active customers and more than 225 in-store veterinary hospitals.
| Metric | 13 weeks ended Oct. 29, 2022 | 13 weeks ended Oct. 30, 2021 | 39 weeks ended Oct. 29, 2022 | 39 weeks ended Oct. 30, 2021 |
|---|---|---|---|---|
| Net sales | $1,501.2 million | $1,443.3 million | $4,458.0 million | $4,292.8 million |
| Comparable-sales growth | 4.1% | 15.5% | 4.3% | 20.9% |
| Gross profit / margin | $597.7 million / 39.8% | $594.7 million / 41.2% | $1,799.8 million / 40.4% | $1,791.1 million / 41.7% |
| Operating income | $48.1 million | $61.9 million | $148.0 million | $183.2 million |
| Net income attributable to Class A and B-1 common stockholders | $19.9 million | $52.8 million | $58.1 million | $135.4 million |
| Adjusted EBITDA / margin | $137.6 million / 9.2% | $138.5 million / 9.6% | $412.1 million / 9.2% | $419.3 million / 9.8% |
Cash flow, debt and liquidity
- For the 39 weeks, operating cash flow was $209.5 million, down from $288.4 million. Capital expenditures were $212.1 million, versus $164.3 million; reported free cash flow, defined as operating cash flow less fixed-asset spending, was negative $2.6 million, versus positive $124.1 million.
- Cash and cash equivalents were $148.7 million at October 29, 2022, down from $211.6 million at January 29, 2022. Management reported total liquidity of $592.6 million, including $443.9 million available under the ABL revolving facility; no revolving borrowings were outstanding.
- First Lien Term Loan principal was $1,674.5 million (carrying value, net of unamortized discount and issuance costs, was $1,652.2 million). Its weighted-average interest rate was 7.0%, versus 4.1% at January 29, 2022. The term loan matures in 2028; the $500 million ABL facility matures in 2026. The company reported compliance with debt covenants.
- Management believed available resources and expected operating cash flows would fund operations, scheduled requirements and planned capital investments for at least the next 12 months.
Material changes and management commentary
- Quarterly sales rose 4.0%, but comparable-sales growth slowed to 4.1% from 15.5% a year earlier. For the 39-week period, sales rose 3.8% and comparable sales rose 4.3%.
- Consumables sales increased 12.0% in the quarter and services and other increased 24.6%; supplies and companion animals fell 9.4%. Management attributed the supplies decline to softer discretionary spending amid inflation and comparison with stimulus-supported prior-year sales. E-commerce sales increased 9.9% in the quarter; services sales increased 14.4%.
- Quarterly gross margin declined 1.4 percentage points. Management cited sales mix, channel impacts, moderate distribution-cost increases and integration costs related to acquiring the remaining interest in the veterinary joint venture.
- Quarterly operating income decreased 22.4%; net income attributable to common stockholders decreased 62.2%. Management cited a $19.2 million lower year-over-year fair-value remeasurement benefit on an investment in Rover and veterinary-joint-venture integration costs. The filing reports $1.6 million of such integration costs in the quarter and $14.7 million year to date.
- Interest expense increased 45.5% in the quarter, primarily due to higher rates on the variable-rate term loan. Year-to-date operating cash flow was pressured by lower operating income, inventory cash needs and payroll and incentive-bonus payments. Capital spending increased, including investments in veterinary hospitals and digital capabilities.
Outlook, risks and unusual items
- The filing provides no specific numerical revenue, earnings or cash-flow guidance.
- In November 2022, after quarter-end, Petco entered into forward-starting interest-rate caps intended to limit rates on a portion of variable-rate debt when the specified three-month SOFR exceeds 4.5%; the caps take effect December 30, 2022 and expire December 31, 2024.
- Management identified inflation, supply-chain constraints, economic and geopolitical developments, competition, consumer demand, vendor reliance, labor, technology and cybersecurity, and access to capital as risks. It said the duration and impact of macroeconomic factors were uncertain.
- Ordinary-course legal matters were disclosed. Management did not expect them to have a material adverse effect, while noting litigation outcomes are inherently uncertain. No material changes to previously disclosed risk factors were reported.
- Management concluded disclosure controls were effective at a reasonable-assurance level as of October 29, 2022; no material change in internal control over financial reporting was reported.
Important facts for investors to verify
- Confirm the period: the filing is for the quarter ended October 29, 2022, not fiscal 2021 Q3.
- Track whether sales growth and comparable sales can persist as discretionary categories remain weak, and whether consumables and services growth offsets that weakness.
- Monitor gross-margin trends, integration spending and the stated causes of the sharp year-over-year net-income decline.
- Assess cash conversion and capital intensity: year-to-date free cash flow was negative despite positive operating cash flow.
- Review variable-rate debt exposure, the effectiveness and coverage of the interest-rate caps, and available ABL borrowing capacity.
- Consider that Adjusted EBITDA and free cash flow are non-GAAP measures; review the filing’s definitions and reconciliations alongside GAAP results.